Standard chemotherapy regimens improve survival for hematologic tumors. For acute myelogenous leukemia, idarubicin and cytarabine is preferred. ABVD is standard for advanced Hodgkin
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Context:
Purpose:
Summary:
Impact: